LINDSEY SHARP: Open Payments
NPI 1134588015 · RUSSELLVILLE, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$526 in 24 payments from 11 companies in 2025. Trend: 2023 $1,048 · 2024 $299 · 2025 $526
Food & beverage: $526
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 5 | $112 |
| Otsuka America Pharmaceutical, Inc. | 4 | $71 |
| Braeburn Inc. | 3 | $68 |
| Teva Pharmaceuticals USA, Inc. | 2 | $52 |
| Vanda Pharmaceuticals Inc. | 2 | $47 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $45 |
| ABBVIE INC. | 2 | $44 |
| Indivior Inc. | 1 | $27 |
| E.R. Squibb & Sons, L.L.C. | 1 | $25 |
| Alkermes, Inc. | 1 | $19 |
Products named: Auvelity, REXULTI, BRIXADI, AUSTEDO XR, HETLIOZ, CAPLYTA, MAVYRET, SUBLOCADE.
Industry payments across AR — which companies pay providers there.
